Proven leader in medtech joins to drive company commercialization and growth
Santa Ana, California, February 1, 2022 – EndoStim, a medical device company developing and commercializing a first-in-class implantable neurostimulation treatment for drug refractory gastroesophageal reflux disease (GERD), announced today that Eric B. Goorno has been appointed as President and Chief Executive Officer. Goorno brings to EndoStim more than 30 years of global leadership experience in the medical device industry, from startups to Fortune 500 companies, including Boston Scientific. Goorno joins EndoStim to lead the company’s rebuilding through the regulatory approval, scale up and commercialization process.
“We are pleased to welcome Eric as CEO of EndoStim, as he brings a track record of driving sustained, profitable growth for diverse health technology and device companies, delivering value for patients and investors,” said Dr. Virender K. Sharma, CMO, Co-Founder and EndoStim Board Member. “Eric’s leadership will guide EndoStim to realize the potential of our transformative therapy for drug refractory GERD, which addresses a range of unmet needs for patients with this disease.”
'I am excited to take on this leadership role at EndoStim at such a pivotal time, as we build the company based on its successes and work to rapidly bring this novel approach to treating GERD patients,” said Eric Goorno, Chief Executive Officer of EndoStim.
Before joining EndoStim, Eric was the Chief Executive Officer and Board Member of LifeSprout, Inc., a Johns Hopkins-based startup developing products for soft tissue replacement and regenerative medicine. Prior to joining LifeSprout, Eric had a long career with Boston Scientific, including his last role as President of the firm’s $395 million Urology & Gynecology Division, where he was responsible for establishing and driving the Division’s global strategy and sustained growth. Earlier at Boston Scientific Eric held positions as Vice President, New Market Development and Strategic Planning, Urology & Gynecology, Vice President of Operations, Microwave Divisions, and Vice President and General Manager, Symbiosis Division. After leaving Boston Scientific in 2009, he founded Pulse Veterinary Technologies, LLC where he served as Founder, CEO and Board Member until the company’s successful acquisition. He then joined his next start up, BioDirection, as President and CEO before being recruited to the CEO position at LifeSprout. Earlier in his career, Eric held various operational roles at Synthes USA, a leader in the orthopedic trauma market. He holds an MBA from Harvard Business School and a BA from Tufts University.
EndoStim is a medical device company developing and commercializing a first-in-class neurostimulation treatment system for drug refractory gastroesophageal reflux disease (GERD). EndoStim therapy is designed to restore normal esophageal function and preserve normal anatomy to avoid the typical gastrointestinal side effects of traditional anti-reflux surgery. The EndoStim System has been successfully investigated in multiple independent studies. For more information, visit www.endostim.com and follow on Twitter-@EndoStim4GERD and LinkedIn.